BIOVIC

What BIOVIC does

BIOVIC (Biovic Sdn Bhd, 692398-D) is a Malaysian biomedical device manufacturer founded in April 2008 and headquartered at a 4,000 square foot facility in Sunway Damansara Technology Park, Petaling Jaya, Selangor. The company specializes in the research, design, development, and manufacture of expanded Polytetrafluoroethylene (ePTFE) vascular grafts under its flagship AVATAR® brand, using a proprietary Humidity Resistant Technology (HRT) and a unique open porous microstructure on both internal and external graft surfaces to promote tissue ingrowth and healing. Its product line spans more than 50 product codes, including tapered configurations and extended lengths up to 75cm for extra-anatomic procedures, all packaged in dual barrier sterile packaging.

The company sells primarily to vascular surgeons, cardiovascular and general surgical specialists, hospitals, and dialysis centers for use in arterial vascular reconstruction, segmental bypass, arteriovenous vascular access (dialysis), and extra-anatomic procedures. BIOVIC generates revenue through one-time hardware sales of AVATAR® grafts on a quote-based per-unit/per-case pricing model, with no disclosed public pricing. Its go-to-market combines direct enterprise sales (including a dedicated U.S. effort led by a 30-year industry veteran) with exclusive regional distribution partnerships — notably Jiangsu Biovic Medical Device Co. Ltd. for China. The company holds ISO 13485:2016 certification (since 2010), MDSAP certification, EU CE Marking under MDR, Medical Devices Authority of Malaysia approval, and BioNexus status, with US FDA clearance in process.

BIOVIC is privately held, with equity investors including Innocorp Ventures Sdn Bhd (subsidiary of Agensi Inovasi Malaysia, since June 2015) and Growing Ocean International of Singapore (since October 2022). The leadership team is led by founder-CEO and CTO Tarun Edwin (25+ years, 37 patents in ePTFE graft technology, ex-Bard Peripheral Vascular) and combines senior operators from Bard, C.R. Bard, Boston Scientific, Becton Dickinson, J&J/Ethicon, and IMPRA. The company is actively compiling clinical evidence through a multi-center post-market comparative study of AVATAR® versus competitor ePTFE grafts to support surgeon adoption.

Name

BIOVIC

Legal name

Biovic Sdn Bhd (692398-D)

Website

https://biovic.com.my

Company type

Private

Founded year

2008

Operating status

Operating

Short description

BIOVIC is a Malaysian biomedical device manufacturer that designs, develops, and produces AVATAR® ePTFE vascular grafts using proprietary Humidity Resistant Technology. It serves vascular surgeons, hospitals, and dialysis centers globally through direct sales and exclusive regional distribution partnerships.

Ownership category

akta.pro rank

Product category

Vascular Grafts (ePTFE Medical Devices)

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF)

akta.pro secondary industries

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• EPTFE vascular grafts
• Biomedical device manufacturing
• Vascular reconstruction devices
• Dialysis access grafts
• Polytetrafluoroethylene medical devices

Headquarters

HQ city

Petaling Jaya

HQ country

Malaysia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. AVATAR® ePTFE Vascular Graft Sales: BIOVIC generates revenue through the sale of its flagship AVATAR® ePTFE Vascular Grafts to healthcare providers, with more than 50 product codes covering a comprehensive range of sizes, tapered configurations, center helix, and extended lengths up to 75cm. Packaged in dual barrier sterile packaging and sold as one-time medical device purchases per procedure.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

BIOVIC researches, designs, develops, and manufactures expanded Polytetrafluoroethylene (ePTFE) vascular grafts, with its flagship AVATAR® Vascular Graft line offered in more than 50 product codes covering tapered configurations, center helix, and extended lengths up to 75cm. The grafts are engineered using BIOVIC's proprietary Humidity Resistant Technology (HRT) and packaged in dual barrier sterile packaging for use in arterial vascular reconstruction, segmental bypass, arteriovenous (dialysis) access, and extra-anatomic procedures by vascular surgeons, hospitals, and dialysis centers globally.

Product overview

BIOVIC offers a single unified medical-device product line built around its flagship AVATAR® ePTFE Vascular Graft, manufactured at a 4,000 sq ft state-of-the-art facility in Petaling Jaya, Malaysia. The core offering is the AVATAR® ePTFE Vascular Graft (a synthetic substitute for veins and arteries used in vascular reconstruction, bypass, and arteriovenous access), produced using BIOVIC's proprietary Humidity Resistant Technology (HRT) and offered in more than 50 product codes including tapered and extended-length (up to 75cm) configurations. The portfolio is a focused, single-product platform-plus-variants architecture rather than a multi-module SaaS suite, with variants (e.g., center helix, step taper, taper helix grafts) all serving the same surgical specialty: vascular repair and replacement.

Differentiator

Problem solved

Functional benefit

Brands

• AVATAR® ePTFE Vascular Graft: Flagship product line of BIOVIC — ePTFE vascular grafts engineered using BIOVIC's proprietary Humidity Resistant Technology (HRT), available in tapered configurations and extended lengths up to 75cm, with more than 50 product codes.

Products and services

• AVATAR® ePTFE Vascular Graft Synthetic ePTFE-based vascular graft engineered using BIOVIC's proprietary Humidity Resistant Technology (HRT) for arterial vascular reconstruction, segmental bypass, arteriovenous (dialysis) vascular access, and extra-anatomic procedures. Features a unique open porous microstructure on both internal and external surfaces to promote tissue ingrowth; available in more than 50 product codes including tapered configurations and extended lengths up to 75cm; packaged in dual barrier sterile packaging; CE marked and sold globally. Targeted at vascular surgeons, hospitals, and dialysis centers.

Quantifiable outcome

• AVATAR® Vascular Graft confirmed equivalent to leading competitor grafts across all critical strength and handling parameters, with superior softness and enhanced handling per clinical evaluations
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Jiangsu Biovic Medical Device Co. Ltd.flagship — exclusive china distribution; access to world's fastest-growing medical device sectorChannel Partner/ Reseller/ Distributor · 1 October 2022Designated as BIOVIC's exclusive distributor for the AVATAR® Vascular Graft in China. China is one of the world's fastest-growing medical device sectors, having sustained double-digit growth for over a decade (reaching $78.8 billion in 2018, a 22% YoY increase). The partnership positions BIOVIC to introduce its innovative products to the Chinese market and solidify its presence in this pivotal region.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Artivion: Cardiovascular and vascular surgery company offering implantable tissues and vascular grafts for cardiac and vascular repair. Competes in adjacent vascular graft indications BIOVIC targets with AVATAR®.
• Cook Medical: Privately held medical device manufacturer with a long-standing vascular graft and interventional product portfolio. Competes with BIOVIC across vascular reconstruction and dialysis access graft segments.
• Becton, Dickinson and Company (BD): Acquired Bard Peripheral Vascular, the prior employer of BIOVIC's CEO/CTO Tarun Edwin and the company where pioneering products (Venaflo™, Distaflo™, Bard Flair™, Fluency™) were developed. BD's Bard peripheral vascular franchise is a direct ePTFE graft competitor.
• W. L. Gore & Associates: Pioneer of ePTFE-based medical devices and the originator of the modern vascular graft category with the GORE-TEX® Vascular Graft line. The dominant incumbent whose products BIOVIC's AVATAR® graft is benchmarked against in clinical claims.
• Getinge: Global medical technology company with a vascular graft portfolio built through the JOTEC acquisition, offering ePTFE grafts for vascular and cardiovascular surgery. Direct competitor in the same vascular graft category BIOVIC serves.
• LeMaitre Vascular: Specialty vascular surgery device company with a portfolio of ePTFE and biologic vascular grafts (including carotid shunt and dialysis access graft offerings), selling directly to vascular surgeons globally. Closest direct competitor to BIOVIC in ePTFE vascular graft market segment.

Broad incumbents

• Abbott Vascular: Major cardiovascular and vascular device player with broad peripheral vascular and endovascular portfolio. Competes for hospital vascular surgery budgets and share-of-suite across the same hospital customers BIOVIC targets.
• Medtronic: Global cardiovascular medical device leader with vascular surgery and endovascular offerings. Indirect competitor to BIOVIC for vascular surgery budgets and procedural volume at large hospitals and academic centers.
• Terumo: Global medical device incumbent with cardiovascular and vascular surgery product portfolios. While not a single-product ePTFE graft specialist, Terumo operates in overlapping vascular surgery categories and competes for hospital budgets.
• Edwards Lifesciences: Cardiovascular device leader with a peripheral vascular franchise that addresses many of the same vascular surgery indications (including vascular reconstruction) that BIOVIC's AVATAR® graft targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOVIC